BSE filing, NSE: CAPLIPOINT. Summary written from the filing by ALFA Finder's alert engine.
Caplin Point Laboratories Ltd: key numbers
- Share price
- ₹2,351.00
- Market cap
- ₹17,870 Cr
- Revenue (annual)
- ₹2,187 Cr
- Net profit (annual)
- ₹641.2 Cr
- P/E (TTM)
- 26.9×Sector 46.5×
- Promoter holding
- 70.57%+0.00% QoQ
- FII holding
- 5.72%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Caplin Point Laboratories Ltd
All →Caplin Point Laboratories Other Announcement
Caplin Point Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI listing regulations.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories concluded its 35th Annual General Meeting on September 25, 2026. Key business included adopting financial statements and approving the final dividend declaration.
Caplin Point Laboratories Price Movement Clarification
Caplin Point Laboratories clarified that the recent increase in its stock's trading volume is market-driven. The company confirmed no undisclosed material information exists regarding this movement.
Caplin Point Laboratories Annual General Meeting
Caplin Point Laboratories Limited scheduled its 35th Annual General Meeting for September 25, 2026. Key agenda items include adopting financial statements and declaring a ₹4 final dividend.
Caplin Point Laboratories Annual Report
Caplin Point Laboratories Limited submitted its Annual Report for FY 2025-26. The company's 35th Annual General Meeting is scheduled for September 25, 2026.
Caplin Point Laboratories Price Movement Clarification
Caplin Point Laboratories has clarified that recent trading volume spikes are market-driven. The company confirms it has no undisclosed price-sensitive information.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.